Antibodies to type II and XI collagens: evidence for the formation of antigen specific as well as cross reacting antibodies in patients with rheumatoid arthritis

KEITH MORGAN,1 CATHERINE BUCKEE,1 IAN COLLINS,1 SHIRLEY AYAD,2 ROY B CLAGUE,1 AND P J LENNOX HOLT1

From the Departments of 1Rheumatology and 2Biochemistry and Molecular Biology, University of Manchester Medical School, Oxford Road, Manchester

SUMMARY Antigen specific and cross reacting antibodies to native and denatured types II and XI collagen were detected in the sera of rats immunised with either of these antigens. The antibodies from rats immunised with type XI collagen initially showed the strongest binding to the α2(XI) chain of type XI collagen but later binding to the α3(XI) chain was seen. Sera from patients with rheumatoid arthritis had antibodies that bound to both type II and XI collagens. Immunoblotting studies showed that most patients had antibodies which bound to the α1(II) chain of type II collagen and to the α3(XI) chain of type XI collagen. Some patients also had antibodies which bound to the α1(XI) and to the α2(XI) chains of type XI collagen. Thus antibodies to unique as well as to common epitopes on each of the two types of collagen molecule occur in some patients with rheumatoid arthritis.

Key words: collagen induced arthritis.

Articular cartilage, which is destroyed in rheumatoid arthritis (RA), contains at least four genetically distinct collagen types: the major type II collagen and the quantitatively minor collagens, types VI, IX, and XI.1 Both type II and type XI (formerly 1α2α3α) collagens have been shown to be arthritogenic and immunogenic in rats.2-5 Solid phase radioimmunoassay has previously shown that antibodies formed to each of these two collagens in the rat bind to the other collagen.5 A role for these antibodies in the production of collagen induced arthritis in the rat has been proposed,6-8 and anticollagen antibodies could play a part in the induction or perpetuation of inflammation in some patients with RA. Antibodies to types II, IX, and XI collagen (native and denatured) have been found in the sera of some patients with RA.9 In this paper we have investigated antibodies to type II and XI collagen in patients with RA and also in rats immunised with these collagens. We present evidence to show that antibodies to both collagens (types II and XI collagen) are formed in patients with RA, and that antibodies to type XI collagen are not solely cross reacting antibodies raised to type II collagen.

Materials and methods

Collagens

Native type II collagen was extracted from bovine nasal septa by pepsin digestion and native type XI collagen from fetal bovine articular cartilage by similar methods. Both collagens were extensively purified by differential salt precipitation and by dialysis against phosphate buffer.9 The collagens were pure by polyacrylamide gel electrophoresis and no uronic acid could be detected by the method of Bitter and Muir,10 indicating that there was no proteoglycan contamination.

The collagens were lyophilised and stored at −20°C. They were dissolved in 0.45 M sodium chloride/0.02 M trometamol (TRIS) buffer pH 7.5 at 2 mg/ml before use.

Rats

Female Wistar rats (45–77 days old) were used. These rats have been inbred in an isolator for seven...
generations from one original pair of non-litter mates. After weaning the rats were kept in a normal animal room used only for animals from this isolator. Similar isolator bred rats of other strains were used for some experiments. These were inbred DA rats, inbred PVG-RT1U, and DA × Wistar crosses. Sprague-Dawley rats were conventionally bred.

**IMMUNISATION OF RATS**

Rats were immunised intradermally on the back with 0.5 ml of an emulsion of native bovine type II collagen (500 μg) and Freund’s incomplete adjuvant (1:1, v/v) or with a similar amount of native type XI collagen. The collagens were dissolved in 0.05 M sodium chloride/0.02 M tretonamol buffer at 2 mg/ml. The rats were given food and water freely and examined for evidence of clinical arthritis and non-articular lesions.

**PATIENTS**

The 46 patients were outpatients or inpatients of the rheumatology departments of the Manchester Royal Infirmary or Withington Hospital, Manchester, or the Royal Devonshire Hospital, Buxton, or of Noble’s Hospital, Douglas, Isle of Man. All patients had definite or classical rheumatoid arthritis.11 As the incidence of anti-native type II collagen antibodies in patients with RA is approximately 10%,9 the patients were selected, for the likely presence of anti-type II collagen antibodies in their sera, from previous data.

**BLOOD SAMPLES**

Blood was collected from patients when they attended the rheumatology clinics. It was allowed to clot at room temperature and centrifuged at 1500 g for seven minutes. The serum was removed and frozen as aliquots at −20°C until used. Control sera were obtained from 29 normal, healthy subjects attending the Regional Blood Transfusion Service.

Blood was collected from rats 14 days after immunisation with collagen or from unimmunised rats for control sera. It was tested as for the human blood.

**DETECTION OF ANTICOLLAGEN ANTIBODIES**

**Enzyme linked immunosorbent assay (ELISA)** IgG antibodies to native and denatured types II and XI collagen were measured in the human and rat sera using a solid phase, double antibody, enzyme labelled immunoassay previously described.9 The results were expressed as arbitrary units between 0 and 1900 (maximum measurable absorbance being 2000 before subtraction of blank wells).

**Immunoblotting assay**

(a) **Electrophoretic separation of the collagen chains.** The individual chains of types XI and II collagen were separated by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis using a Bio-Rad Mini Protein II cell. The collagens were denatured by heating at 95°C for five minutes in a reducing buffer (0.0625 M tris(methyl) HCl pH 6.8 with 2 M urea, 0.05 M dithiorthiol, 10% glycerol, 2% SDS, and 0.01% bromphenol blue) before electrophoresis. Aliquots (10 μl) of 1.6 μg of type II collagen and of 4.8 μg of type XI collagen were applied to adjacent wells of a 3% stacking gel and electrophoresed into a 4% polyacrylamide gel for 30 minutes at constant voltage (200 volts) at room temperature. This gave equal concentrations of each of the three individual α1(XI), α2(XI), and α3(XI) chains of type XI collagen with the α1(II) chains of type II collagen. The gels were then equilibrated for 30 minutes at room temperature in transfer buffer (see below).

(b) **Western blotting of the collagen chains.** After separation as above the chains of types II and XI collagen were electrophoretically transferred from the SDS-polyacrylamide gel onto nitrocellulose according to the method of Towbin et al.13 The transfer buffer used was 25 mM tris(methyl) HCl/192 mM glycine buffer pH 8.3 containing 20% v/v methanol. The transfer time was 17 hours at 30 volts followed by two hours at 60 volts. After transfer the nitrocellulose membrane was cut into strips with each strip having one lane of type II collagen and one of type XI collagen. These strips were then used for the detection of anticollagen antibodies in the human or rat sera (next section).

(c) **Immunodetection of anticollagen antibodies.** IgG antibodies to the individual α chains of types II and XI collagen were detected using the nitrocellulose strips from the Western blotting. The strips were incubated at room temperature in phosphate buffered saline (PBS) (as used in the ELISA) containing 1.0% w/v low-fat milk and 0.5% w/v Tween (PBS/Tween/low fat milk) for 1.75 hours to block any remaining protein binding sites on the nitrocellulose. They were then incubated for one hour at room temperature in the appropriate serum samples, which were diluted 1:1000 in PBS/Tween/low fat milk. After washing three times with PBS/Tween they were incubated for one hour at room temperature with alkaline phosphatase labelled antihuman IgG (Dako Ltd) diluted 1:2000 or antirat IgG (Serotec Ltd) diluted 1:1000 in PBS/Tween/low fat milk. The same antibodies were used in the ELISA. After washing three times in PBS/Tween the strips were washed thoroughly in 0.15 M veronal acetate buffer...
pH 9.6 to remove any traces of Tween. The strips were then developed at room temperature in substrate (0.005% of 5-bromo-4-chloroindolyl phosphate and 0.01% nitroblue tetrazolium in veronal acetate buffer with 4 mM magnesium chloride) to detect anti-IgG bound to any anticollagen antibodies attached to the χ chains on the membranes.

After development the strips were washed free of unreacted substrate with distilled water and dried at 37°C between layers of filter paper. Normal sera were always included with each batch of samples tested.

**Results**

**ELISA**

**Rat sera**

Thirteen of the 15 Wistar rats immunised with native type XI collagen and four of the six rats immunised with native type II collagen developed an inflammatory arthritis 14–23 days after immunisation (median onset: 15 days for both collagens). Unimmunised rats did not develop arthritis.

Table 1 shows the mean absorbance value, standard deviation, and the upper limit of normal (mean + three standard deviations) for 10 normal Wistar rat sera and the levels of antibody in the immunised rats for native and denatured types II and XI collagen. From the ELISA results it can be seen that all the immunised rats developed antibodies to the immunising collagen and had antibodies which bound to both its native and denatured form. The level of antibody to the cross reacting antigen was, in general, very low compared with the level of antibody in rats immunised with that collagen type.

Thus antibodies that bound to both collagen types and antibodies that did not cross react were produced in these rats after immunisation with either collagen. Most of the antibodies produced were non-cross reacting and thus to epitopes specific for each antigen.

**Human sera**

Table 2 shows the mean absorbance value, standard deviation, and the upper limit of normal (mean + three standard deviations) for the 29 normal blood donors for native and denatured types II and XI collagen in the ELISA. Table 2 also shows the number of positive sera (out of the 46 patients) for each antigen and the level of antibodies for each antigen. Forty one (89%) of the sera were positive for antibodies to native type II collagen, 40 (87%) positive for antibodies to denatured type II, 27 (59%) positive for antibodies to denatured type XI collagen, and only eight (17%) positive for antibodies to native type XI collagen. Two patients were negative for antibodies to native type II collagen but had antibodies to denatured type II collagen. The level of antibody to denatured type XI in one of these patients was proportionally much higher than...
Table 3 Binding of antibodies from rat sera to the α chains of types II and XI collagen detected by immunoblotting

<table>
<thead>
<tr>
<th>Type XI immunised rats (n=15)</th>
<th>Type II immunised rats (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade*</td>
<td>Total No</td>
</tr>
<tr>
<td></td>
<td>+ve</td>
</tr>
<tr>
<td>Type II α chains</td>
<td>0</td>
</tr>
<tr>
<td>Type XI α(XI) chain</td>
<td>0</td>
</tr>
<tr>
<td>Type XI α2(XI) chain</td>
<td>0</td>
</tr>
<tr>
<td>Type XI α1(XI) chain</td>
<td>0</td>
</tr>
</tbody>
</table>

*Grade 5=dark staining (greatest amount of antibody); grade 1=light staining (smallest amount of antibody).

the level to denatured type II collagen as compared with the other patients. Also, many patients had antibodies to denatured type II collagen but no antibodies to denatured type XI collagen. These findings suggest that some patients produce antibodies specifically to type XI collagen and that antibodies to type XI collagen are not only antibodies raised to type II collagen which cross react with type XI collagen.

**IMMUNOBLOTTING**

**Rat sera**

The antibodies from the six Wistar rats immunised 14 days previously with native type II collagen showed binding to the α1(II) chain of type II collagen, and from five rats to the α3(XI) chain of type XI collagen (Table 3). No binding of antibodies to the α1(XI) or α2(XI) chains was seen. Normal rat sera showed no binding to any of the chains under these conditions. Similarly sera from 23 other rats (16 Wistar, three DA, two PVG-RT1U, and two DA×Wistar cross) immunised in separate experiments with native type II collagen and Freund's incomplete adjuvant also contained antibodies that bound only to the α1(II) chain of type II collagen and to the α3(XI) chain of type XI collagen. In general the binding to the α1(II) chain of type II collagen was stronger than the binding to the α3(XI) chain of type XI collagen.

The antibodies from the 13 of the 15 Wistar rats immunised with native type XI collagen only showed binding to the α2(XI) chain of the three chains of type XI collagen with no binding to the α1(II) chains of type II collagen (Table 3). No binding to either collagen could be detected with the other two sera. Thus the immunoblotting technique did not detect the very low levels of antibody to denatured type II collagen seen in these sera using the ELISA technique (Table 1). Sera from three of these rats bled on days 39 and 101 after immunisation also showing binding to the α3(XI) chain of type XI collagen and to the α1(II) chain of type II collagen. Sera from seven Sprague Dawley rats which had been immunised with type XI collagen 21 days previously also showed binding only to the α2(XI) chain of type XI collagen. Again antibodies in the serum of one of these rats bled 50 days after immunisation showed binding also to the α3(XI) chain of type XI collagen and to the α1(II) chain of type II collagen, suggesting a change in the specificity of the antibody produced.

**Human sera**

Table 4 details the number of patients' sera that showed the presence of antibodies to denatured types II and XI collagens as detected by immunoblotting. About the same number of sera showed binding to type II collagen as were seen in the ELISA (Table 2). A greater number of sera were positive to type XI collagen than in the ELISA, but many of these showed only weak binding (11 sera at grade 1). There was a good correlation between the strength of binding to the α1(II) chain of type II collagen and the α3(XI) chain of type XI collagen (r=0.9108), suggesting that these were either the same antibodies binding to similar epitopes on each molecule or that patients producing antibodies to type II collagen also tended to produce antibodies to type XI collagen. Sixteen patients also had antibodies to the α2(XI) chain of type XI collagen (Table 4), and in these patients there was a strong

Table 4 Binding of antibodies from the 46 sera of patients with RA to the α chains of types II and XI collagen detected by immunoblotting

<table>
<thead>
<tr>
<th>Grade*</th>
<th>Total No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+ve</td>
</tr>
<tr>
<td>Type II α chains</td>
<td>3</td>
</tr>
<tr>
<td>Type XI α3(XI) chain</td>
<td>2</td>
</tr>
<tr>
<td>Type XI α2(XI) chain</td>
<td>0</td>
</tr>
<tr>
<td>Type XI α1(XI) chain</td>
<td>0</td>
</tr>
</tbody>
</table>

*Grade 5=dark staining (greatest amount of antibody); grade 1=light staining (smallest amount of antibody).*
correlation between the strength of binding to the α2(XI) and to the α3(XI) chain of type XI collagen \((\rho = 0.4350)\). Three patients had antibodies which bound to the α1(XI) chain of type XI collagen. One of the patients showed very strong binding to the α1(XI) chain of type XI collagen, and this particular patient had no antibodies to native type II collagen in the ELISA and her antibodies to denatured type II collagen were proportionally lower than those to denatured type XI collagen as compared with the patients generally.

Discussion

Antibodies that bound to both native and denatured types II and XI collagen were seen in the rats immunised with either of these antigens and in some patients with RA. The α1(XI) and α2(XI) chains of type XI collagen are biochemically similar to, but genetically distinct from, the α1(V) and the α2(V) chains of type V collagen but have no similarity with the α1(II) chain of type II collagen.\(^1\) From its amino acid composition and CNBr peptide pattern, however, the α3(XI) chain of type XI collagen is similar to the α1(II) chain of type II collagen, though it is more highly glycosylated.\(^2\) Thus one would expect that any antibodies that bound to the α1(II) chain of type II collagen and also cross reacted with type XI collagen would bind only to the α3(XI) chain of type XI collagen and that antibodies raised to type XI collagen would only cross react with type II collagen if they bound to the α3(XI) chain of the type XI collagen. Antibodies to conformational determinants, which are lost on denaturation of the molecules, may also occur.

From the ELISA on the rat sera it seemed that both cross reacting and non-cross reacting antibodies were produced when they were immunised to either type II or type XI collagen. Confirmation for the presence of non-cross reacting antibodies to the denatured collagens was seen by the immunoblotting technique as rats immunised with type XI collagen initially showed the presence of antibodies to the α2(XI) chain only.

The ELISA on human sera suggested that a proportion of antibodies was raised specifically to type II collagen as some sera showed no binding to type XI collagen. It was not clear, however, whether antibodies specific to type XI collagen were present as all sera with anti-type XI collagen antibodies also had antibodies to type II collagen. The immunoblotting technique showed that antibodies to type XI collagen were present as binding of antibodies to the α1(XI) and to the α2(XI) chains of type XI collagen occurred in some patients as well as binding of antibodies to the α3(XI) chain. It is possible that these could be antibodies raised to type V that cross react with type XI collagen. This is less likely as type V collagen is a minor, but widespread, component of virtually all non-cartilaginous tissues, whereas type XI collagen is present in the cartilage, and this is tissue that is being broken down in RA.

Thus the ELISA and immunoblotting techniques demonstrated that type XI collagen is immunogenic and that antibodies can be specifically formed to it both in rats and in patients with RA. This finding has implications for both the rat model of collagen induced arthritis and for the role of antibodies to collagen in RA.

If antibodies to type II collagen are important in the induction of type II collagen induced arthritis and the arthritis in rats immunised with type XI collagen is induced in a similar manner (that is by antibodies that cross react with type II collagen), then these results suggest that the antibodies required to induce arthritis only bind to a small number of common epitopes on the two molecules. The inhibition of type II collagen induced arthritis can be achieved by intravenous administration of type II collagen before intradermal challenge with this antigen,\(^3\) and this treatment also suppresses the production of anti-type II collagen antibodies. Similarly, administration of type XI collagen intravenously before intradermal challenge with type XI collagen suppresses both the humoral response to type II collagen and the induction of arthritis (KM personal observation). Thus further examination of antibodies to common and to unique epitopes on these molecules and their relation to arthritis induction and to cartilage destruction in the rat may enable a better understanding of the role of these antibodies in patients with RA.

The findings in this paper suggest that antibodies to unique epitopes as well as to common epitopes of each of the two types of collagen molecule (types II and XI) occur in patients with RA. Some of these antibodies may be important in the development of arthritis in some patients and others may just be markers of existing or potential cartilage destruction. Type XI collagen appears to be less widely distributed in cartilage than is type II collagen, with preferential location around chondrocytes.\(^4\) \(^5\) The chondrocytes are more pronounced in the deeper zones of articular cartilage, and so antibodies unique to type XI collagen, which do not occur in all patients with RA, may be useful markers of severe cartilage destruction. Also, if the antibodies caused damage to the matrix around the chondrocytes then the viability of the chondrocytes might be affected and lead to further cartilage loss. Thus antibodies to different epitopes on these collagen molecules may have different roles in rheumatoid arthritis.
As antibodies unique to type II and unique to type XI collagen occur in some patients with RA then, if these antibodies are pathogenic, any treatment might have to affect the response to both collagens to be effective. The inhibition of type II collagen induced arthritis by type XI collagen (see above) suggests that this may be possible by a common mechanism.

This work was supported by grants from the Arthritis and Rheumatism Council. One of us (IC) was supported by the Devonshire Royal Infirmary, Buxton and Miss Angela Thompson at the Manchester Royal Infirmary for collection of the blood samples and Mrs Doreen Ward for typing the manuscript.

References

12 Morris N P, Bachinger H P. Type XI collagen is a heterotrimer with the composition (1a2a3a) retaining non-triple-helical domains. Journal of Biological Biochemistry 1987; 262: 11345-50.

Antibodies to type II and XI collagens 1013